Keens T, Hoffman V, Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen Reyes M, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508
Camprodon-Rosanas E, Ribas-Fito N, Batlle-Vila S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Sluggish cognitive tempo: sociodemographic, behavioral, and clinical characteristics in a population of Catalan school children. J Atten Disord. 2017 Jun;21(8):632-41. doi: 10.1177/1087054716652477
Camprodon-Rosanas E, Ribas-Fito N, Batlle S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Association between sluggish cognitive tempo symptoms and attentional network and working memory in primary schoolchildren. J Atten Disord. 2017 Apr 1. doi: 10.1177/1087054717702245
Vilor-Tejedor N, Alemany S, Forns J, Caceres A, Murcia M, Macia D, Pujol J, Sunyer J, Gonzalez JR. Assessment of susceptibility risk factors for ADHD in imaging genetic studies. J Atten Disord. 2016 Aug 17.
Deal LS, Sleeper-Triplett J, DiBenedetti DB, Nelson L, McLeod L, Haydysch EE, Brown TM. Development and validation of the ADHD Benefits of Coaching Scale (ABCS). J Atten Disord. 2015 Mar;19(3):191-9. doi: 10.1177/1087054714558118
Offen W, Chuang-Stein C, Dmitrienko A, Copley-Merriman K. Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the PhRMA. Drug Inf J. 2007;4:31-46.
Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. Drug Inf J. 2000;34(4):1273-91.
Renck-Hooper U, McKenna SP, Whalley D. Measuring quality of life in female urinary urge incontinence: development and psychometric properties of the IQoLI. J Drug Assess. 1998;1:41-8.
Ciociola AA, Webb DD, McSorley DJ. The continued use of placebo-controlled clinical trials in the study of peptic ulcer disease: a sponsor perspective. Drug Inf J. 1996 Apr;30(2):433-9.
Doward LC. Developing a measure of quality of life for patients with recurrent genital herpes. Drug Inf J. 1994 Jan 1;28(1):19-25.
Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.